Wednesday, July 8, 2026

Drug profile · INN

deferiprone

deferiprone (FERRIPROX) is a unknown. Associated with Chiesi Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

FDA: approved EMA: approved TGA: approved Various (V03) V03AC02
US status approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — deferiprone
US status
approved
Class
Various (V03)
Route
ORAL
Patents
0
Programs
1
Data quality
0.84

Quick answer

deferiprone (FERRIPROX) is a unknown. Associated with Chiesi Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN deferiprone
Brand FERRIPROX
Mechanism Unknown
Therapeutic class Various (V03)
Route ORAL
Formulation SOLUTION
ATC code V03AC02

Mechanism of action

Unknown

Approval history

Authority Status Date
FDA approved
EMA approved
TGA approved

Pipeline programs

  1. Deferiprone oral solution Phase 3 · BRIGHT MINDS BIOSCIENCES · Pantothenate Kinase-Associated Neurodegeneration

Related & competitor drugs

  1. besilesomab Various (V09)
  2. deferasirox Various (V03)
  3. ferric citrate coordination complex Various (V03)
  4. folic acid Various (V04)
  5. sevelamer carbonate Various (V03)
  6. sugammadex sodium Various (V03)

Frequently asked questions

What is deferiprone?

deferiprone (FERRIPROX) is a unknown. Associated with Chiesi Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for deferiprone?

FERRIPROX is a marketed brand name for deferiprone. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of deferiprone?

deferiprone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.